Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis
NCT Number:
NCT03222609
Phase:
II
Protocol Type:
Treatment
Age Group:
Adult
Disease Sites:
Other Hematopoietic
Study Objectives:
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
If you would like to contact a MUSC study team member to learn more information about this study, click
HERE.